Site Editor

David S. Ettinger, MD, FACP, FCCP


Use of Patritumab Deruxtecan in EGFR Inhibitor–Resistant NSCLC

By: Vanessa A. Carter, BS
Posted: Friday, January 28, 2022

Pasi A. Jänne, MD, PhD, of the Dana-Farber Cancer Institute, Boston, and colleagues evaluated the safety and efficacy of patritumab deruxtecan—an antibody–drug conjugate consisting of a HER3 antibody (HER3-DXd)—in EGFR inhibitor–resistant, EGFR-mutated non–small cell lung cancer (NSCLC). Published in Cancer Discovery, the results of their study showed that HER3-DXd demonstrated clinical activity among known and unknown EGFR tyrosine kinase–resistant mechanisms, suggesting it may be of future use as a treatment option for patients with this type of lung cancer.

This phase I, open-label study enrolled 81 patients with locally advanced or metastatic, EGFR inhibitor–resistant, EGFR-mutated NSCLC. Participants were administered 3.2 to 6.4 mg/kg of HER3-DXd intravenously on day 1 of each 21-day cycle (n = 36). The dose-expansion cohort (n = 45) received the recommended dose for escalation (5.6 mg/kg) as either a frozen liquid or a lyophilized drug product.

The median treatment duration was 5.5 months, and a total of 57 patients received HER3-DXd at 5.6 mg/kg. The median number of prior therapy lines was four, and all patients previously received an EGFR tyrosine kinase inhibitor; resistance to these inhibitors was identified in 78% of participants.

Treatment-emergent adverse events were reported in all patients, with the most common being nausea (60%) and fatigue (64%). Events of grade 3 or higher, such as thrombocytopenia (26%), neutropenia (15%), and fatigue (10%), were reported in 64% of individuals. 

The median progression-free survival was 8.2 months. The confirmed objective response rate was 39%, and confirmed responses occurred at a similar frequency among subgroups regardless of prior tyrosine kinase inhibitor; those who did not receive chemotherapy had an objective response rate of 63% and a median progression-free survival of 7.6 months. Of note, patients defined as having early clearance of circulating tumor DNA exhibited a higher response rate (68% vs. 19%) and longer progression-free survival (8.3 vs. 4.4 months) than those who did not.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.